Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00959556
NCT00959556CompletedNot Applicable

Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting

Centre Oscar Lambret1 site in 1 country900 target enrollmentStarted: November 28, 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
900
Locations
1
Primary Endpoint
Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)
Study OverviewEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to chemotherapy.

PURPOSE: This clinical trial is studying blood samples in patients with breast cancer.

Detailed Description

OBJECTIVES:

  • Identify constitutional gene variants associated with a change in response.

OUTLINE: Blood samples are collected periodically for analysis of genetic factors.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to 120 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •DISEASE CHARACTERISTICS:
  • •Histologically confirmed breast carcinoma
  • •Received first-line chemotherapy (in neoadjuvant or metastatic setting) comprising anthracyclines and/or taxanes, including for a second primary cancer
  • •Patient agrees to conservative surgery
  • •Hormone receptor status not specified
  • •PATIENT CHARACTERISTICS:
  • •Menopausal status not specified
  • •No contraindication for chemotherapy comprising anthracyclines and/or taxanes
  • •PRIOR CONCURRENT THERAPY:
  • •See Disease Characteristics
  • •No prior adjuvant therapy

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Study of Biomarkers in Blood and/or Tumor Tissue Samples From Patients With Ductal Carcinoma in Situ and From Healthy VolunteersBreast Cancer
NCT00935233Queen Mary University of London6,000
Completed
Not Applicable
Trastuzumab in Treating Women With Metastatic Breast CancerBreast Cancer
NCT00896376Centre Antoine Lacassagne49
Unknown
Not Applicable
Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United KingdomProstate Cancer
NCT00758173Cancer Research UK2,000
Unknown
Not Applicable
Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United KingdomOvarian Cancer
NCT00757263Cancer Research UK2,000
Unknown
Not Applicable
Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United KingdomEndometrial Cancer
NCT00758056Cancer Research UK2,000